Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and genomic correlates of imatinib response in melanomas with KIT alterations.

British journal of cancer - 1 Nov 2022

Jung Seungyeon, Armstrong Emma, Wei Alexander Z, Ye Fei, Lee Aaron, Carlino Matteo S, Sullivan Ryan J, Carvajal Richard D, Shoushtari Alexander N, Johnson Douglas B

Abstract excerpt

BACKGROUND: Imatinib is an active agent for some patients with melanoma harbouring c-KIT alterations. However, the genetic and clinical features that correlate with imatinib sensitivity are not well-defined. METHODS: We retrospectively evaluated 38 KIT-altered melanoma patients from five medical centres who received imatinib, and pooled data from prospective studies of imatinib in 92 KIT-altered melanoma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Genomics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Melanoma

Share to Mutation

Share to Proto-Oncogene Proteins c-kit

Source

Open in PubMed Open full text

Identifiers

PMID: 35999272
DOI: 10.1038/s41416-022-01942-z
PMCID: PMC9596433

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and genomic correlates of imatinib response in melanomas with KIT alterations.PMID 35999272Read ↗

Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.Semantic proximity Read ↗

Imatinib targeting of KIT-mutant oncoprotein in melanoma.Semantic proximity Read ↗

KIT and Melanoma: Biological Insights and Clinical Implications.Semantic proximity Read ↗

KIT gene mutations and copy number in melanoma subtypes.Semantic proximity Read ↗

KIT mutations in a series of melanomas and their impact on treatment with imatinib.Semantic proximity Read ↗

Functional and sensitivity profiling of the <i>KIT</i> Mutation Landscape in MelanomaSemantic proximity Read ↗

KIT as a therapeutic target in metastatic melanoma.Semantic proximity Read ↗

Molecular Profiling and Novel Therapeutic Strategies for Mucosal Melanoma: A Comprehensive ReviewSemantic proximity Read ↗

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.Semantic proximity Read ↗

The clinical significance of KIT mutations in melanoma: a meta-analysis.Semantic proximity Read ↗

Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report.Semantic proximity Read ↗

MET amplification correlates with poor prognosis and immunotherapy response as a subtype of melanoma: a multicenter retrospective study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.